Member Info for twix386

Yes Boyzee that's my take as further funding was mentioned that was not only to be excused as standard going concern. There are two issues. Is the fact that we are told off the record that funding will not be needed just days later material news that should be issued publicly and can it be relied upon.

Mmmm Didn't he also say we reached b/e earlier this year! Wonder why recent results indicated further funding would be likely. When things are said and they happen I can't complain. When they don't happen with some consistency. one never knows if future comments can be relied on. Let's hope the results expectations of funding requirement is already out if date.

Anyone know what TW says in today's bearcast about yesterday's meeting and Premaitha discourse?

How did the conversation go with TW, as rightly after funding mess and share price retrace he was planning to ask some tough questions? Any hints on newsflow?

Seems TW's reaction is a carbon copy to mine! He remains as a buy but fails this time to mention it reiterate any price target.

Inspite of being a large holder I did not like today's rns. Seeing through it as a weak attempt to support that looks what it is. Let's have some real new material news!

So much for the new boss! Even if finncap messed up, we never looked to include pi's and option award at 10p us an insult! I always say this, but when news comes judt before agm if usual service is delivered , it would still serve to hold bod to account on this and ask if this year's doubtless spun and promise for progress and news will see sp taking note as its been said each year along with a lower sp!!

TW latest,... I am looking forward to grilling Premaitha (NIPT) at the Nigel Wray London seminar on 16 October. There are still a few places going and its free – details HERE. Meanwhile we have three pieces of news this week following that rather disappointing placing at 10p two Friday's ago caused by the a’hole behaviour of the toads at FinnCap. Yes this is Tom Winnifrith writing… The very good news is that the group’s Yourgene Bioscience division has signed a deal with a “leading clinical research organisation in Taiwan” to deliver next generation sequencing (NGS) testing in oncology.Under the terms of the partnership, Yourgene will provide genetic testing services using NGS technology on patient samples gathered by the Partner for the purpose of research into early stage cancer screening. We are told that this is the first phase of collaboration between Yourgene and the Partner and further project phases are anticipated in the future. The initial phase is anticipated to generate approximately $1 million of revenues over the next 6-12 months. Well that all helps the drive towards break-even. A few more deals like this will do no harm at all. We also had some director dealings. First up Barry Hextall bought 100,000 shares at 10p. It is not much but I suppose better than nothing. Following the acquisition, Mr Hextall's beneficial interest in the Company is 432,518 ordinary shares, 0.1% of the issued share capital. We are also told that: ”In addition, further to the appointment of Hayden Jeffreys to the Board announced 3 October 2018, Mr Jeffreys has been awarded share options over 3,000,000 ordinary shares, exercisable at 10 pence per share subject to the existing Company scheme rules.” Ends. This makes me angry. Over at Optibiotix (OPTI) options vest at a 100% premium to the share price at issue. That is an incentive. Options are meant to be an incentive. Premaitha options seem to v est at a share price which has been dragged low by in-house incompetence. This is not an incentive. If Premaitha’s share price just matches inflation of. Say 2%, then in five years this is a free £30,000 for lucky Hayden who will not have had to risk a cent. We shareholders who risk our capital would have, uncder this scenario, have underperformed the market big time and in real terms be no better off at all. Such option programmes steal wealth from those who risk capital and transfer it to those who do not, management fat cats. This is just not acceptable. And it is one reason why folks respect the board at Optibiotiox while, right now, thinking Premaitha is run by a bunch of a’holes. Notwithstanding this, another matter I plan to raise on the 16th, the stance remains BUY with a target to sell of c21p.

Yes, though Hextall last purchased at 18p. He's not been a very good or savvy investor so far with his own money. Expect this time he may do better

Florida, Do you really think news has absolutely no impact until the shares are fully submitted?

Opportunity at AGM to ask what year will shareholder value deliver on the promised bright future described at each of the previous AGM's?

Yes bakky. The question was could others supercede our test rather than could we improve it.

I suppose a mother's blood test isn't going to be beaten anytime soon, but the method and cost of testing would be the area for a cheaper test if it were possible. Right now the workflow is the blessing and the curse. Blessing as with current science know-how the complex workflow limits entry and competition. Curse because that very fact perhaps opens up quicker/cheaper future test methods. Perhaps one day mothers blood will be tested at the GP on a regular visit for instance.

Post year end sales have continued to surge – in the first half of this year ( ie the six months to 30 September, they will be 40% ahead at £3.8 million and the settlement with Illumina should add to that rate of growth. Thus while the company will report a small – but funded – loss for this year to March 31 next year it will report a profit at a group level of, quite possibly, seven figures. The year after I’d be looking for up to £4 million with £7 million or more on the cards the year after. The company flags that it may need more working capital as it expands but if it is profitable as it will be that does not need to come in the form of equity. A business capable of generating a pre and post tax profit of £7 million by the year to 31 March 2022 should not be valued at £39 million as it is today ( post new shares and at 10p). The surge at top and bottom lines implies a forward PE in the mid-teens. Discounting back at 10% per annum that suggests a 6 month price target of c£85 million or 21.6p. Maybe the rating given to such growth once the business is profitable will be even higher. This placing feels like a kick in the gonads. Well it is. Finncap deserve a collective knee-capping. Not only are they a firm staffed by sanctimonious and conceited knob-heads but they are useless at the job they are vastly overpaid to do. My only hope, given how Finncap has screwed up this placing, is that some of the bucket shops it tapped up forward sold, i.e. engaged in wholesale insider dealing, and will not now get stock and will be forced to close

Tom Winnifrith writes: We ordinary shareholders in Premaitha (LSE:NIPT) have suffered for many years and shown enormous loyalty. News released well after the market close of a £2.5 million placing at 10p might thus seem like a kick in the teeth by a management treating us with contempt. I am afraid the story is far worse. The company says it is a bookbuild. Fear not it has been done and settled. Here is what happened and why. The cash will be used to buy up Illumina inventory as part of the settlement announced ;llast week. So it is a working capital issue nothing else. Premaitha knew it would need the cash two weeks ago and approached broker FinnCap to raise the cash. The shares were then over 12p and subsequently hit 15p after the Illumina deal with Finncap on the road and promising that a fund raise would be easy. On Tuesday night this week the Finncap knobheads said they could get it done at just 7p having trawled the bucket shops at the bottom end of AIM. Premaitha chairman Adam Reynolds had a fit and it is he who has raised the cash (on Thursday and today) with firm holders and no bucket shops involved. The share price slide back to 11.9p before Reynolds was able to take control was a result of the interaction between FinnCap and the bucket shops who will not now be involved in this issue. That FinnCap thinks going to bucket shops, giving shares away at a massive discount and charging 5% is a fair way to treat corporate clients is just another sign that it is institutionally useless and run by A Grade ******s. Its efforts of the past week have seriously fecked the share price but as long as it got its 5% commission and gets its £3,500 pcm retainer does it care? It is this sort of behaviour which gives the City such a bad name. Why did Finncap not suggest that we ordinary shareholders get to participate via Primary Bid? Because we are smelly little people, plebs and it doesn’t give a flying feck about our interests. It is not as if we will meet them at the Polo tomorrow is it? Or as if we will be picking our kids up from the same school gates as these City slackers. Results for the year to March 31 2018 were well flagged. Revenues increased by 100% to £6.15 million, including the first full year of contribution from Yourgene Bioscience, which was acquired in March 2017. Like for like sales growth was 37%. Gross profit increased by 250% to £3.17 million and the gross margin improved by 10 points to 52% thanks to benefits of scale, geographic mix and reduced product costs. But thanks in part to litigation expenses admin expenses surged to £11.8 million although the operating loss before litigation expenses reduced by 18% to £5.91 million. Cash at the year end was just £280,000 but since May and including today the company has raised £5.5 million in equity. Post year end sales have continued to surge – in the first half of this year ( ie the six months to 30 September,

Wonder if Steven Myers has subscribed for even more as its been said AR ended up going to his mates.

Have to wonder why the directors wanted to take part with significant subscription when the future is sooooo bad. Probably because with litigation over and new broom laying the groundwork for his tenure after a choppy aftermath the news will propel us back to 15p+ this year

bump

It could be choppy, but with news that I expect is lined up it will be just one more bumo in the road that gets left behind along with those in the D&VSDI (derampers and Vendetta.......)

Thanks andyken